PMID- 30235967
OWN - NLM
STAT- MEDLINE
DCOM- 20190626
LR  - 20190626
IS  - 1563-5279 (Electronic)
IS  - 0020-7454 (Linking)
VI  - 129
IP  - 3
DP  - 2019 Mar
TI  - Direct and indirect evidences of BDNF and NGF as key modulators in depression: 
      role of antidepressants treatment.
PG  - 283-296
LID - 10.1080/00207454.2018.1527328 [doi]
AB  - PURPOSE: Depression is one of the most prevalent, recurrent and life-threatening 
      mental illnesses. However, the precise mechanism underlying the disorder is not 
      yet clearly understood. It is therefore, essential to identify the novel 
      biomarkers which may help in the development of effective treatment. METHODS: In 
      this milieu, the profile of the brain-derived neurotrophic factor (BDNF) and 
      nerve growth factor (NGF) were considered as biomarkers in the light of 
      pathophysiology of depression and its treatment. RESULTS: Previously, we have 
      reported that BDNF level in the postmortem brain of suicide victims was 
      significantly lower than those of normal controls. We also found decreased BDNF 
      levels in the specific brain regions of the learned helplessness model of 
      depression in rat, and was found to increase normal level following chronic 
      fluoxetine hydrochloride treatment. NGF is another important member of 
      neurotrophin, which is dysregulated in the pathophysiology of depression in some 
      models of peripheral nerve damage and stress. The results shown evidences of the 
      effect of antidepressants on modulating depression via the NGF in preclinical and 
      clinical models of depression, but conflicted, therefore make it currently 
      difficult to affirm the therapeutic role of antidepressants. CONCLUSIONS: Here, 
      we review some of the preclinical and clinical studies aimed at disclosing the 
      role of BDNF and NGF mediated pathophysiological mechanisms of depression and the 
      new therapeutic approaches targeting those key molecules. In addition, an 
      important link between BDNF, NGF and depression has been discussed in the light 
      of current existing knowledge.
FAU - Mondal, Amal Chandra
AU  - Mondal AC
AD  - a Laboratory of Cellular and Molecular Neurobiology , School of Life Sciences, 
      Jawaharlal Nehru University , New Delhi , India.
FAU - Fatima, Mahino
AU  - Fatima M
AD  - a Laboratory of Cellular and Molecular Neurobiology , School of Life Sciences, 
      Jawaharlal Nehru University , New Delhi , India.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20181127
PL  - England
TA  - Int J Neurosci
JT  - The International journal of neuroscience
JID - 0270707
RN  - 0 (Antidepressive Agents)
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 9061-61-4 (Nerve Growth Factor)
SB  - IM
MH  - Animals
MH  - Antidepressive Agents/*pharmacology
MH  - *Brain/drug effects/metabolism
MH  - *Brain-Derived Neurotrophic Factor/drug effects/metabolism
MH  - *Depressive Disorder/drug therapy/metabolism
MH  - Humans
MH  - *Nerve Growth Factor/drug effects/metabolism
OTO - NOTNLM
OT  - Anti-depressants
OT  - BDNF
OT  - NGF
OT  - hippocampus
OT  - major depressive disorder
OT  - neurogenesis
EDAT- 2018/09/22 06:00
MHDA- 2019/06/27 06:00
CRDT- 2018/09/22 06:00
PHST- 2018/09/22 06:00 [pubmed]
PHST- 2019/06/27 06:00 [medline]
PHST- 2018/09/22 06:00 [entrez]
AID - 10.1080/00207454.2018.1527328 [doi]
PST - ppublish
SO  - Int J Neurosci. 2019 Mar;129(3):283-296. doi: 10.1080/00207454.2018.1527328. Epub 
      2018 Nov 27.